fig3

Figure 3. Expression profiles of five miRNAs and their respective ROC curves during the verification phase. The study examined serum samples from 84 individuals with RCC and 84 HCs. Analysis revealed significantly decreased expression of (A) miR-30a-5p, (C) miR-124-3p, (G) let-7b-5p, and (I) miR-302d-3p in RCC patients’ serum. Conversely, (E) miR-221-3p showed significant upregulation; ROC analysis yielded the following AUC values: (B) 0.651 for miR-30a-5p [95%confidence interval (CI): 0.584-0.713], (D) 0.703 for miR-124-3p (95%CI: 0.638-0.763), (F) 0.696 for miR-221-3p (95%CI: 0.631-0.756), (H) 0.708 for let-7b-5p (95%CI: 0.644-0.768), and (J) 0.628 for miR-302d-3p (95%CI: 0.561-0.691). Asterisks indicate statistical significance levels: * P < 0.05, ** P < 0.01, *** P < 0.001. In the Figures, ROC curves are displayed in red, with green curves showing the 95% confidence intervals and blue lines representing the diagonal. RCC: Renal cell carcinoma; miRNAs: microRNAs; ROC: receiver operating characteristic; HCs: healthy controls.